Global Type 1 Diabetes Treatment
Market Report
2024
Type 1 diabetes treatment market size is USD 8154.2 million in 2024 and will expand at a compound annual growth rate (CAGR) of 8.00% from 2024 to 2031.
The base year for the calculation is 2023 and 2019 to 2023 will be historical period. The year 2024 will be estimated one while the forecasted data will be from year 2025 to 2031. When we deliver the report that time we updated report data till the purchase date.
PDF Access: Password protected PDF file, Excel File Access: Quantitative data, PPT Report Access: For the presentation purpose, Cloud Access: Secure Company Account Access.
Share your contact details to receive free updated sample copy/pages of the recently published edition of Type 1 Diabetes Treatment Market Report 2024.
According to Cognitive Market Research, the global type 1 diabetes treatment market size is USD 8154.2 million in 2024 and will expand at a compound annual growth rate (CAGR) of 8.00% from 2024 to 2031.
Base Year | 2023 |
Historical Data Time Period | 2019-2023 |
Forecast Period | 2024-2031 |
Global Type 1 Diabetes Treatment Market Sales Revenue 2024 | $ 8154.2 Million |
Global Type 1 Diabetes Treatment Market Compound Annual Growth Rate (CAGR) for 2024 to 2031 | 8% |
North America Type 1 Diabetes Treatment Market Sales Revenue 2024 | $ 3261.68 Million |
North America Type 1 Diabetes Treatment Compound Annual Growth Rate (CAGR) for 2024 to 2031 | 6.2% |
Europe Type 1 Diabetes Treatment Market Sales Revenue 2024 | $ 2446.26 Million |
Europe Type 1 Diabetes Treatment Compound Annual Growth Rate (CAGR) for 2024 to 2031 | 6.5% |
Asia Pacific Type 1 Diabetes Treatment Market Sales Revenue 2024 | $ 1875.47 Million |
Asia Pacific Type 1 Diabetes Treatment Compound Annual Growth Rate (CAGR) for 2024 to 2031 | 10% |
South America Type 1 Diabetes Treatment Market Sales Revenue 2024 | $ 407.71 Million |
South America Type 1 Diabetes Treatment Compound Annual Growth Rate (CAGR) for 2024 to 2031 | 7.4% |
Middle East and Africa Type 1 Diabetes Treatment Market Sales Revenue 2024 | $ 163.08 Million |
Middle East and Africa Type 1 Diabetes Treatment Compound Annual Growth Rate (CAGR) for 2024 to 2031 | 7.7% |
Market Split by Product |
|
Market Split by End User |
|
List of Competitors |
|
Regional Analysis |
|
Country Analysis |
|
Key Qualitative Information Covered |
|
Report scope is customizable as we have a huge database of Type 1 Diabetes Treatment industry. We can deliver an exclusive report Edition/Consultation as per your data requirements. Request for your Free Sample Pages.
Type 1 Diabetes Treatment Market is Segmented as below. Particular segment of your interest can be provided without any additional cost. Download the Sample Pages!
Type 1 diabetes treatment encompasses a range of therapies aimed at managing this chronic condition characterized by the body's inability to produce insulin. Insulin replacement remains the cornerstone, typically administered through injections or insulin pumps, to regulate blood sugar levels effectively. Additionally, dietary management, regular monitoring of blood glucose, and exercise are integral parts of treatment to maintain optimal health and prevent complications. Advancements in medical technology, such as continuous glucose monitoring and artificial pancreas systems, continue to improve the management of type 1 diabetes, enhancing patients' quality of life and reducing the risk of long-term complications.
Heightened awareness about the importance of early diagnosis is instrumental in increasing sales within the Type 1 Diabetes Treatment Market. Early detection enables prompt initiation of treatment, reducing the risk of complications and improving long-term outcomes. As individuals become more educated about the signs and symptoms of diabetes, they are more likely to seek medical attention, leading to higher diagnosis rates. Additionally, healthcare professionals advocating for routine screenings and preventive measures contribute to early identification, driving demand for diabetes management products and services. Ultimately, prioritizing early diagnosis not only benefits individual health but also boosts sales within the market.
In January 2023, Abbott revealed that the U.S. Food and Drug Administration (FDA) has granted approval for its Proclaim XR spinal cord stimulation (SCS) system for treating painful diabetic peripheral neuropathy (DPN), a severe diabetes-related complication. The Proclaim XR SCS system offers relief for DPN patients seeking alternatives to conventional treatments like oral medication. Furthermore, individuals using therapy from the Proclaim XR SCS system will gain access to Abbott's NeuroSphere Virtual Clinic, an integrated care application enabling remote communication with physicians for treatment adjustments.
Continuous innovation in insulin delivery systems drives sales by addressing key patient needs and preferences. Advanced devices offer greater convenience, accuracy, and ease of use, enhancing patient adherence to treatment regimens. For example, the development of insulin pumps with features like automated insulin delivery and remote monitoring capabilities provides more precise insulin dosing and reduces the burden of manual injections. Additionally, the integration of continuous glucose monitoring (CGM) technology with insulin pumps enables real-time glucose monitoring and automatic insulin adjustments, improving glycaemic control and reducing the risk of hypoglycaemia. Furthermore, innovations such as patch pumps, smart insulin pens, and implantable devices offer diverse options catering to individual preferences and lifestyles. As patients seek more personalized and technologically advanced solutions, the market for innovative insulin delivery systems is poised for sustained growth.
Supportive healthcare policies play a crucial role in propelling the Type 1 Diabetes Treatment Market by creating an environment conducive to research, development, and access to innovative therapies. Government initiatives such as subsidies for insulin and medical devices, reimbursement policies, and healthcare infrastructure investments can significantly impact market growth. For instance, reimbursement schemes that cover the costs of continuous glucose monitoring (CGM) systems and insulin pumps encourage patient adoption and drive market expansion. Furthermore, policies promoting diabetes education, screening programs, and early intervention contribute to better disease management and reduce long-term healthcare costs associated with complications. Additionally, regulations mandating quality standards and safety protocols ensure the availability of reliable and effective treatment options, fostering trust among patients and healthcare providers. Overall, supportive healthcare policies are instrumental in enhancing patient access, improving outcomes, and driving the growth of the Type 1 Diabetes Treatment Market.
Limited access to healthcare poses a significant hindrance to sales in the Type 1 Diabetes Treatment Market. Inadequate healthcare infrastructure, particularly in rural and underserved areas, restricts patients' ability to receive timely diagnosis, access medications, and avail themselves of essential diabetes management services. This lack of access exacerbates disparities in care and contributes to suboptimal disease management, leading to poorer health outcomes and increased healthcare costs in the long run. Furthermore, limited access to healthcare facilities and specialist providers impedes patient education, self-management skills, and adherence to treatment regimens, resulting in a higher burden of diabetes-related complications. Addressing barriers to healthcare access through improved infrastructure, telemedicine solutions, community outreach programs, and healthcare policy reforms is essential for ensuring equitable access to diabetes care and driving market growth in underserved regions.
The COVID-19 pandemic has significantly impacted the Type 1 Diabetes Treatment Market. Disruptions in healthcare services, lockdown measures, and resource reallocation strained diabetes management efforts, leading to delays in diagnosis, treatment interruptions, and reduced access to care for many patients. Additionally, supply chain disruptions disrupted insulin and medical device distribution, exacerbating treatment shortages and increasing costs. Telemedicine adoption surged to bridge gaps in patient-provider communication, offering remote consultations and monitoring. However, economic downturns and job losses affected affordability and insurance coverage, further complicating access to medications and treatment. Furthermore, the pandemic's psychological toll, including stress and anxiety, may have exacerbated glycemic control issues among patients. Moving forward, the market's recovery relies on restoring healthcare infrastructure, strengthening telemedicine capabilities, and addressing socioeconomic disparities exacerbated by the pandemic.
We have various report editions of Type 1 Diabetes Treatment Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.
The Type 1 Diabetes Treatment Market exhibits a competitive landscape characterized by ongoing innovation, strategic collaborations, and robust R&D efforts. Companies vie for market share through product differentiation, pricing strategies, and expansion into emerging markets, driving competition and fostering advancements in treatment modalities.
Top Companies Market Share in Type 1 Diabetes Treatment Industry: (In no particular order of Rank)
If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.
According to Cognitive Market Research, North America dominated the market in 2024 and accounted for around 40% of the global revenue due to several factors. Firstly, the region boasts advanced healthcare infrastructure and high levels of awareness about diabetes management, leading to increased diagnosis and treatment rates. Moreover, a large diabetic population, coupled with favourable reimbursement policies and robust R&D activities, drives market growth. Additionally, the presence of key market players and continuous technological advancements contribute to the dominance of North America in revenue generation within the Type 1 diabetes treatment market.
Asia-Pacific is the fastest-growing region fuelled by various factors. Rising disposable incomes, urbanization, and changing lifestyles contribute to an increasing prevalence of type 1 diabetes, expanding the market. Moreover, improving healthcare infrastructure, government initiatives to combat diabetes, and growing awareness drive demand for treatment options. Additionally, the region benefits from a large underserved population, offering significant growth opportunities for market expansion. Furthermore, collaborations between international pharmaceutical companies and local stakeholders facilitate the introduction of innovative therapies, accelerating market growth in Asia-Pacific.
The current report Scope analyzes Type 1 Diabetes Treatment Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com
The above graph is for illustrative purposes only. To learn more about geographical trends request the free sample pages. Contact US!
According to Cognitive Market Research, the global type 1 diabetes treatment market size was estimated at USD 8154.2 Million out of which North America held the major market of around 40% of the global revenue with a market size of USD 3261.68 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.2% from 2024 to 2031. Sales of type 1 diabetes treatment in North America are poised for growth due to the region's robust healthcare infrastructure and increasing prevalence of the condition. Rising adoption of advanced insulin delivery systems and continuous glucose monitoring technologies, alongside favourable reimbursement policies, drives market expansion. Moreover, the emphasis on preventive care and early intervention strategies by healthcare providers contributes to higher diagnosis rates and treatment initiation. In particular, the rapid-acting insulin segment is expected to thrive, supported by technological advancements and patient preference for convenient dosing options in this region.
Country Analysis
According to Cognitive Market Research, with a market value of USD 8154.2 million in 2024 and projected to expand at a compound annual growth rate (CAGR) of 6.5% from 2024 to 2031. Europe accounted for a share of around 30% of the global market size of USD 2446.26 million. The type 1 diabetes treatment market in Europe is forecasted to witness significant growth owing to increasing awareness about diabetes management and rising healthcare expenditure. Technological innovations in insulin delivery systems and glucose monitoring devices drive market penetration, especially in countries with high diabetes prevalence rates. Additionally, collaborative efforts between pharmaceutical companies and healthcare providers to develop personalized treatment regimens foster market expansion. Long-acting insulin segment is expected to dominate, driven by its efficacy in providing basal insulin coverage and reducing the risk of hypoglycaemia, particularly in the European market.
According to Cognitive Market Research, the global type 1 diabetes treatment market size was estimated at USD 8154.2 Million out of which Asia Pacific held the market of around 23% of the global revenue with a market size of USD 1875.47 million in 2024 and will grow at a compound annual growth rate (CAGR) of 10.0% from 2024 to 2031. In the Asia Pacific region, sales of type 1 diabetes treatment are expected to surge due to factors such as rapid urbanization, changing lifestyles, and increasing disposable incomes. Growing healthcare infrastructure and rising awareness about diabetes management contribute to higher diagnosis rates and treatment uptake. Furthermore, the adoption of telemedicine and digital health solutions enhances patient access to care, particularly in remote areas. The rapid growth of the medium-acting insulin segment is anticipated, driven by its affordability and suitability for diverse patient populations across Asia Pacific.
According to Cognitive Market Research, the global type 1 diabetes treatment market size was estimated at USD 8154.2 Million out of which Latin America market of around 5% of the global revenue with a market size of USD 407.71 million in 2024 and will grow at a compound annual growth rate (CAGR) of 7.4% from 2024 to 2031. Sales of type 1 diabetes treatment in Latin America are projected to increase due to improving healthcare infrastructure and rising healthcare expenditure. Government initiatives aimed at diabetes prevention and management drive awareness and diagnosis rates, contributing to market growth. Additionally, increasing adoption of insulin pumps and continuous glucose monitoring systems enhances treatment efficacy and patient outcomes. The short-acting insulin segment is expected to lead in this region, fuelled by its versatility in managing postprandial glucose levels and flexibility in dosing adjustments to accommodate dietary variations common in Latin American diets.
According to Cognitive Market Research, the global type 1 diabetes treatment market size was estimated at USD 8154.2 Million out of which Middle East and Africa held the major market of around 2% of the global revenue with a market size of USD 163.08 million in 2024 and will grow at a compound annual growth rate (CAGR) of 7.7% from 2024 to 2031. The MEA region's type 1 diabetes treatment market is set to expand due to improving access to healthcare services and increasing diabetes prevalence rates. Rising investments in healthcare infrastructure and government initiatives to combat chronic diseases drive market growth. Additionally, the adoption of telemedicine and mobile health solutions improves diabetes management, particularly in underserved areas. The long-acting insulin segment is anticipated to dominate in this region, supported by its efficacy in providing sustained basal insulin coverage, essential for managing diabetes in resource-constrained settings like the Middle East and Africa.
Global Type 1 Diabetes Treatment Market Report 2024 Edition talks about crucial market insights with the help of segments and sub-segments analysis. In this section, we reveal an in-depth analysis of the key factors influencing Type 1 Diabetes Treatment Industry growth. Type 1 Diabetes Treatment market has been segmented with the help of its Product, End User , and others. Type 1 Diabetes Treatment market analysis helps to understand key industry segments, and their global, regional, and country-level insights. Furthermore, this analysis also provides information pertaining to segments that are going to be most lucrative in the near future and their expected growth rate and future market opportunities. The report also provides detailed insights into factors responsible for the positive or negative growth of each industry segment.
According to Cognitive Market Research, rapid-acting insulin held the major market share over the forecast period due to its crucial role in managing postprandial glucose levels effectively. Increased adoption stems from its rapid onset of action and convenience, particularly for patients requiring precise mealtime dosing. Moreover, advancements in delivery systems enhance patient adherence and comfort, further driving sales. Additionally, the rising prevalence of type 1 diabetes and the growing demand for insulin analogy contribute to the sustained dominance of rapid-acting insulin in the market.
Long-acting insulin is the fastest-growing category over the forecast period due to its pivotal role in providing basal insulin coverage. Continuous innovations result in extended duration formulations, reducing the frequency of injections and enhancing patient convenience. Moreover, the increasing adoption of long-acting analogy over traditional insulins propels segment growth. Additionally, the rising emphasis on glycaemic control and the expansion of treatment options in emerging markets contribute to the accelerated sales of long-acting insulin.
The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Type 1 Diabetes Treatment Industry. Request a Free Sample PDF!
According to Cognitive Market Research, hospitals and clinics hold a prominent market share due to their role as primary points of care for type 1 diabetes patients. Their widespread availability and comprehensive services attract a large patient pool. Additionally, these facilities often serve as referral centres for complex cases, further bolstering their market share. Moreover, advancements in diabetes management technologies integrated into hospital systems enhance treatment outcomes, driving sales.
Specialty centres is the fastest-growing category over the forecast period due to their specialized expertise and focus on diabetes care. Patients increasingly seek specialized treatment options and personalized care, leading to higher demand for services provided by specialty centres. Furthermore, collaborations with pharmaceutical companies and research institutions facilitate access to cutting-edge therapies and clinical trials, further driving segment growth. Additionally, the rising prevalence of diabetes-related complications necessitates specialized care, contributing to the accelerated sales of specialty centre services.
The above Graph is for representation purposes only. This chart does not depict actual Market share. Please purchase the Type 1 Diabetes Treatment market report 2024 Edition by contacting our team.
Research Associate at Cognitive Market Research
Anushka Gore is a seasoned market researcher specializing in the dynamic landscape of the Pharmaceutical industry. With a keen analytical mind and a deep passion for healthcare advancements, she has dedicated herself unraveling the intricate market trends and consumer behaviors that shape the future of medical technologies and services.
Anushka is a highly motivated and detail-oriented research analyst with a passion for uncovering valuable insights from data. Her expertise in Market Research and business intelligence has equipped her with the skills necessary to analyze complex information and provide strategic recommendations. She thrives in dynamic environments where her analytical abilities and research expertise can contribute to informed decision-making for businesses
I played a pivotal role in conducting market research and competitive analysis. I have a demonstrated ability to synthesize diverse data sources, identify trends, and translate findings into actionable recommendations. My collaborative approach facilitated effective communication of insights, fostering a data-driven culture within the organization. I am committed to maintaining excellence through continuous learning and staying ahead of industry trends. Regular participation in conferences and professional development opportunities keeps my skills sharp and relevant.
Disclaimer:
Product | Rapid-Acting Insulin, Short-Acting Insulin, Medium-Acting Insulin, Long-Acting Insulin, Others |
End User | Hospitals and Clinics, Specialty Centers, Others |
List of Competitors | Abbott Laboratories, Bayer AG, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson Ltd, Merck & Co, Pfizer Inc, Takeda Pharmaceutical, AstraZeneca PLC, XOMA Corp, Others |
This chapter will help you gain GLOBAL Market Analysis of Type 1 Diabetes Treatment. Further deep in this chapter, you will be able to review Global Type 1 Diabetes Treatment Market Split by various segments and Geographical Split.
Chapter 1 Global Market Analysis
Global Market has been segmented on the basis 5 major regions such as North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.
You can purchase only the Executive Summary of Global Market (2019 vs 2024 vs 2031)
Global Market Dynamics, Trends, Drivers, Restraints, Opportunities, Only Pointers will be deliverable
Chapter 2 North America Market Analysis
Purchase Add-Ons to Customize the Report Edition and get further granular data level data about the North America market. Add-On Cost: Request before placing the order, Respective Pricing will be informed after sending the inquiry
Qualitative Analysis for the North America Market: North America Type 1 Diabetes Treatment Market Trends North America Type 1 Diabetes Treatment Technological Road Map North America Type 1 Diabetes Treatment Market Drivers North America Type 1 Diabetes Treatment Market Restraints North America Type 1 Diabetes Treatment Market Opportunity Market Attractiveness Analysis COVID – 19 Impact Analysis PESTEL Analysis Porter’s Five Forces Analysis Product Life Cycle Industrial Chain Analysis
You can purchase only the Executive Summary North America Market (2019 vs 2024 vs 2031)
Chapter 3 Europe Market Analysis
You can purchase only the Executive Summary Europe Market (2019 vs 2024 vs 2031)
Chapter 4 Asia-Pacific Market Analysis
You can purchase only the Executive Summary Asia Pacific Market (2019 vs 2024 vs 2031)
Chapter 5 South America Market Analysis
You can purchase only the Executive Summary South America Market (2019 vs 2024 vs 2031)
Chapter 6 Middle East and Africa Market Analysis
You can purchase only the Executive Summary Middle East and Africa Market (2019 vs 2024 vs 2031)
Only Available with Corporate User License
Chapter 7 Top 10 Countries Analysis
Competitor's Market Share and Revenue (Subject to Data Availability for Private Players)
Chapter 8 Competitor Analysis (Subject to Data Availability (Private Players))
(Subject to Data Availability (Private Players))
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Chapter 9 Qualitative Analysis (Subject to Data Availability)
Segmentation Product Analysis 2019 -2031, will provide market size split by Product. This Information is provided at Global Level, Regional Level and Top Countries Level The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 10 Market Split by Product Analysis 2019 -2031
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 11 Market Split by End User Analysis 2019 -2031
This chapter helps you understand the Key Takeaways and Analyst Point of View of the global Type 1 Diabetes Treatment market
Chapter 12 Research Findings
Here the analyst will summarize the content of entire report and will share his view point on the current industry scenario and how the market is expected to perform in the near future. The points shared by the analyst are based on his/her detailed in-depth understanding of the market during the course of this report study. You will be provided exclusive rights to interact with the concerned analyst for unlimited time pre purchase as well as post purchase of the report.
Why Rapid-Acting Insulin have a significant impact on Type 1 Diabetes Treatment market? |
What are the key factors affecting the Rapid-Acting Insulin and Short-Acting Insulin of Type 1 Diabetes Treatment Market? |
What is the CAGR/Growth Rate of Hospitals and Clinics during the forecast period? |
By type, which segment accounted for largest share of the global Type 1 Diabetes Treatment Market? |
Which region is expected to dominate the global Type 1 Diabetes Treatment Market within the forecast period? |
Segmentation Level Customization |
|
Global level Data Customization |
|
Region level Data Customization |
|
Country level Data Customization |
|
Company Level |
|
Additional Data Analysis |
|
Additional Qualitative Data |
|
Additional Quantitative Data |
|
Service Level Customization |
|
Report Format Alteration |
|
Published Report Editions
are Just a Tip of an Iceberg
Access the Complete Database of
Type 1 Diabetes Treatment Market
Request Sample